Sequential intensive chemotherapy followed by autologous or allogeneic transplantation for refractory lymphoma

Autor:	Adomah Opong, June Greenberg, Richard R. Furman, Adriana C Rossi, Michelle Pasciolla, Koen van Besien, Adrienne A. Phillips, Yuliya S. Jhanwar, Usama Gergis, Tsiporah B. Shore, Peter Martin, Tomer M Mark, John P. Leonard, Grace Suhu, Sarah C. Rutherford, Kathleen Maignan, Sebastian Mayer, Jessy Ryan, Danielle Guarneri, Roger N. Pearse, Calvin Koo, Jia Ruan, Maria Baldo, Jingmei Hsu, Edwidge Cuvilly, Nina Orfali
Rok vydání:	2021
Předmět:	Bendamustine Cancer Research medicine.medical_specialty Allogeneic transplantation Lymphoma medicine.medical_treatment Salvage therapy Hematopoietic stem cell transplantation Transplantation Autologous 03 medical and health sciences 0302 clinical medicine immune system diseases hemic and lymphatic diseases Antineoplastic Combined Chemotherapy Protocols medicine Humans Transplantation Homologous Salvage Therapy business.industry Hematology medicine.disease Surgery Transplantation surgical procedures operative Oncology 030220 oncology & carcinogenesis Refractory lymphoma Stem cell business 030215 immunology medicine.drug
Zdroj:	Leukemia & Lymphoma. 62:1629-1638
ISSN:	1029-2403 1042-8194
Popis:	We evaluate the safety of bendamustine as a bridge to stem cell transplantation (SCT) in patients with relapsed/refractory lymphoma and residual disease after salvage therapy. Thirty-four subjects without complete responses (CR) received bendamustine 200 mg/m
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::911dd92cb25b6dcea33d0a9bc249e096 https://doi.org/10.1080/10428194.2021.1881516 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.